Prograf (Tacrolimus) Patent Expiration, LOE Window & CMS Spending

Prograf (Tacrolimus) by Astellas Pharma: FDA Orange Book LOE 2028-07-16, 10 AB generics, $12.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstellas Pharma
FDA Application & PathwayN050708 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-07-16
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors10
2024 CMS Total Public Spend$12.3M
2024 Medicare Part D Spend$4.0M
2024 Medicaid Spend$8.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.